Lucy Codrington
Stock Analyst at Jefferies
(3.15)
# 2,470
Out of 4,423 analysts
36
Total ratings
45.2%
Success rate
7.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Lucy Codrington
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EPA: IVA Inventiva S.A. | Maintained: Buy | €7.50 | $3.06 | +145.50% | 2 | Jan 28, 2026 | |
| EPA: NANO Nanobiotix S.A. | Maintained: Buy | €9.50 → €21.00 | $30.32 | -30.74% | 4 | Oct 6, 2025 | |
| BME: ALM Almirall, S.A. | Maintained: Buy | €17.00 → €17.50 | $11.12 | +57.37% | 2 | Aug 15, 2025 | |
| BME: ORY Oryzon Genomics S.A. | Maintained: Buy | €2.30 → €4.00 | $3.14 | n/a | 3 | Mar 25, 2025 | |
| EPA: IPN Ipsen S.A. | Maintained: Hold | €110.00 | $156.50 | n/a | 2 | Jan 30, 2025 | |
| ZLDPF Zealand Pharma A/S | Maintained: Buy | $171 | $44.75 | n/a | 8 | Dec 20, 2024 | |
| AMS: PHARM Pharming Group N.V. | Initiated Coverage: Buy | €1.40 | $1.13 | n/a | 1 | Dec 9, 2024 | |
| PHAR Pharming Group | Initiated Coverage: Buy | $14 | $12.87 | n/a | 1 | Dec 9, 2024 | |
| AMS: VVY Vivoryon Therapeutics N.V. | Maintained: Hold | €0.70 → €2.50 | $1.10 | n/a | 3 | Jul 22, 2024 | |
| AIM: CLBX CelLBxHealth plc | Maintained: Buy | 75p | $1.78 | n/a | 5 | Jan 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | zł 37.50 | $20.25 | n/a | 1 | Mar 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | 255p → 340p | $131.40 | n/a | 4 | Jul 5, 2019 |
Inventiva S.A.
Jan 28, 2026
Maintained: Buy
Price Target: €7.50
Current: $3.06
Upside: +145.50%
Nanobiotix S.A.
Oct 6, 2025
Maintained: Buy
Price Target: €9.50 → €21.00
Current: $30.32
Upside: -30.74%
Almirall, S.A.
Aug 15, 2025
Maintained: Buy
Price Target: €17.00 → €17.50
Current: $11.12
Upside: +57.37%
Oryzon Genomics S.A.
Mar 25, 2025
Maintained: Buy
Price Target: €2.30 → €4.00
Current: $3.14
Upside: n/a
Ipsen S.A.
Jan 30, 2025
Maintained: Hold
Price Target: €110.00
Current: $156.50
Upside: n/a
Zealand Pharma A/S
Dec 20, 2024
Maintained: Buy
Price Target: $171
Current: $44.75
Upside: n/a
Pharming Group N.V.
Dec 9, 2024
Initiated Coverage: Buy
Price Target: €1.40
Current: $1.13
Upside: n/a
Pharming Group
Dec 9, 2024
Initiated Coverage: Buy
Price Target: $14
Current: $12.87
Upside: n/a
Vivoryon Therapeutics N.V.
Jul 22, 2024
Maintained: Hold
Price Target: €0.70 → €2.50
Current: $1.10
Upside: n/a
CelLBxHealth plc
Jan 1, 2024
Maintained: Buy
Price Target: 75p
Current: $1.78
Upside: n/a
Mar 30, 2022
Initiated Coverage: Buy
Price Target: zł 37.50
Current: $20.25
Upside: n/a
Jul 5, 2019
Reiterated: Buy
Price Target: 255p → 340p
Current: $131.40
Upside: n/a